Pioneering 3D Human Tissues for Drug Discovery

May 14 | 2024

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Read More »

May 08 | 2024

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Read More »

Apr 15 | 2024

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Read More »